Disabling erratic myoclonus during lamotrigine therapy with high serum level - Report of two cases

J. Janszky, G. Rásonyi, P. Halász, Sarah Olajos, József Perényi, A. Szűcs, Jószef Debreczeni

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

We present two patients with epilepsy who experienced disabling myoclonic jerks during lamotrigine treatment. Both were young males who had intractable cryptogenic generalized epilepsy since childhood. They received a lamotrigine-valproate combination resulting in an excellent improvement; however, after 2-3 years of therapy, both patients were hospitalized because of continuous disabling myoclonic jerks. The dosage of lamotrigine was the same before and at the onset of myoclonus. When the severe myoclonus started, both patients had a higher serum lamotrigine level (16.5 and 17.7 mg/L, respectively) than in previous findings. Disabling myoclonus was also present during lamotrigine monotherapy with 15 mg/L serum level. Lamotrigine may severely worsen myoclonic phenomena in generalized epilepsies, in which adverse events may be dependent on drug serum level.

Original languageEnglish
Pages (from-to)86-89
Number of pages4
JournalClinical Neuropharmacology
Volume23
Issue number2
DOIs
Publication statusPublished - Mar 2000

Fingerprint

Myoclonus
Serum
Generalized Epilepsy
Epilepsy
Therapeutics
Valproic Acid
lamotrigine
Pharmaceutical Preparations

Keywords

  • Adverse events
  • Drug serum level
  • Epilepsy
  • Lamotrigine
  • Myoclonus

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Disabling erratic myoclonus during lamotrigine therapy with high serum level - Report of two cases. / Janszky, J.; Rásonyi, G.; Halász, P.; Olajos, Sarah; Perényi, József; Szűcs, A.; Debreczeni, Jószef.

In: Clinical Neuropharmacology, Vol. 23, No. 2, 03.2000, p. 86-89.

Research output: Contribution to journalArticle

@article{38bb7abd50654394a83236bfbb9010ba,
title = "Disabling erratic myoclonus during lamotrigine therapy with high serum level - Report of two cases",
abstract = "We present two patients with epilepsy who experienced disabling myoclonic jerks during lamotrigine treatment. Both were young males who had intractable cryptogenic generalized epilepsy since childhood. They received a lamotrigine-valproate combination resulting in an excellent improvement; however, after 2-3 years of therapy, both patients were hospitalized because of continuous disabling myoclonic jerks. The dosage of lamotrigine was the same before and at the onset of myoclonus. When the severe myoclonus started, both patients had a higher serum lamotrigine level (16.5 and 17.7 mg/L, respectively) than in previous findings. Disabling myoclonus was also present during lamotrigine monotherapy with 15 mg/L serum level. Lamotrigine may severely worsen myoclonic phenomena in generalized epilepsies, in which adverse events may be dependent on drug serum level.",
keywords = "Adverse events, Drug serum level, Epilepsy, Lamotrigine, Myoclonus",
author = "J. Janszky and G. R{\'a}sonyi and P. Hal{\'a}sz and Sarah Olajos and J{\'o}zsef Per{\'e}nyi and A. Szűcs and J{\'o}szef Debreczeni",
year = "2000",
month = "3",
doi = "10.1097/00002826-200003000-00005",
language = "English",
volume = "23",
pages = "86--89",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Disabling erratic myoclonus during lamotrigine therapy with high serum level - Report of two cases

AU - Janszky, J.

AU - Rásonyi, G.

AU - Halász, P.

AU - Olajos, Sarah

AU - Perényi, József

AU - Szűcs, A.

AU - Debreczeni, Jószef

PY - 2000/3

Y1 - 2000/3

N2 - We present two patients with epilepsy who experienced disabling myoclonic jerks during lamotrigine treatment. Both were young males who had intractable cryptogenic generalized epilepsy since childhood. They received a lamotrigine-valproate combination resulting in an excellent improvement; however, after 2-3 years of therapy, both patients were hospitalized because of continuous disabling myoclonic jerks. The dosage of lamotrigine was the same before and at the onset of myoclonus. When the severe myoclonus started, both patients had a higher serum lamotrigine level (16.5 and 17.7 mg/L, respectively) than in previous findings. Disabling myoclonus was also present during lamotrigine monotherapy with 15 mg/L serum level. Lamotrigine may severely worsen myoclonic phenomena in generalized epilepsies, in which adverse events may be dependent on drug serum level.

AB - We present two patients with epilepsy who experienced disabling myoclonic jerks during lamotrigine treatment. Both were young males who had intractable cryptogenic generalized epilepsy since childhood. They received a lamotrigine-valproate combination resulting in an excellent improvement; however, after 2-3 years of therapy, both patients were hospitalized because of continuous disabling myoclonic jerks. The dosage of lamotrigine was the same before and at the onset of myoclonus. When the severe myoclonus started, both patients had a higher serum lamotrigine level (16.5 and 17.7 mg/L, respectively) than in previous findings. Disabling myoclonus was also present during lamotrigine monotherapy with 15 mg/L serum level. Lamotrigine may severely worsen myoclonic phenomena in generalized epilepsies, in which adverse events may be dependent on drug serum level.

KW - Adverse events

KW - Drug serum level

KW - Epilepsy

KW - Lamotrigine

KW - Myoclonus

UR - http://www.scopus.com/inward/record.url?scp=0343619428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343619428&partnerID=8YFLogxK

U2 - 10.1097/00002826-200003000-00005

DO - 10.1097/00002826-200003000-00005

M3 - Article

C2 - 10803798

AN - SCOPUS:0343619428

VL - 23

SP - 86

EP - 89

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -